Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Gemini EM Fluorescence Microplate Reader

Product Description
The Gemini™ EM Fluorescence Microplate Reader exemplifies flexibility for fluorescence assays. Reading 6 to 384-well microplates, the optical design of the instrument can be switched from top to bottom read modes for improved sensitivity to solutions and cell-based assays. Dual monochromators for variable wavelength selection between 250 nm and 850 nm eliminate the need for searching out the right pair of excitation and emission filters and wavelength scanning across a range of wavelengths in increments as small as 1 nm can be used to optimize assay parameters. Up to 4 wavelength pairs can be read for endpoint and kinetic measurements, and the Gemini EM Microplate Reader offers well scanning to report a fluorescent measurement from a single point in the center of a microplate well to multiple points across a tissue culture well.

Unlike most fluorescence readers that may saturate out with signal intensities over 3 orders of magnitude, the patented AutoPMT Optimization System of the Gemini EM Microplate Reader adjusts the fluorescence detector to each sample well's concentration and normalizes the raw data, extending the dynamic range of assays so that low and high signals can be captured from the same plate. This calibration against an internal standard provides an additional benefit in being able to confidently compare relative fluorescence units (RFUs) of individual samples across plates and readers.

The Gemini EM Microplate Reader is supplied with SoftMax® Pro Data Acquisition & Analysis Software, Molecular Devices' industry leading all-in-one data acquisition and analysis software. Additionally, the Gemini EM Microplate Reader can be seamlessly integrated with the StakMax® Microplate Handling System through the SoftMax Pro Software.
Product Gemini EM Fluorescence Microplate Reader
Company Molecular Devices Product Directory
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Molecular Devices Product Directory
1311 Orleans Drive Sunnyvale, CA 94089-11361 United States

Tel: 1-800-635-5577
Fax: 1-408-548-6439
Email: om@moldev.com



Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!